News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Ipsen Biopharmaceuticals, Inc.
NEWS
JOBS
IN THE PRESS
NEWS
Job Trends
Allergan Rival Ipsen to Continue U.S. Hiring Spree
March 13, 2015
·
3 min read
Biotech Beach
The Day In Review: Tercica, Inc. And Ipsen Sign Cross-License Deal
July 19, 2006
·
1 min read
Business
Ipsen Joins Pfizer In Breast Cancer Trials
October 19, 2005
·
1 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Policy
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury
June 9, 2022
·
7 min read
Genetown
Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
May 26, 2022
·
20 min read
Policy
Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
May 3, 2022
·
13 min read
Business
Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022
April 27, 2022
·
14 min read
Genetown
Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) Designed to Improve Patient Experience
March 16, 2022
·
13 min read
Genetown
Ipsen: New Patient-Reported Data Demonstrated High Satisfaction Levels and Fewer Patients Reporting Injection-site Pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide)
March 8, 2022
·
14 min read
Drug Development
Ipsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER Trial
February 15, 2022
·
14 min read
Business
Ipsen Presents Strong Full-Year 2021 Results and Enters Into Exclusive Negotiations to Divest Its Consumer Healthcare Business
February 11, 2022
·
43 min read
Policy
Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
January 24, 2022
·
7 min read
Business
Ipsen Nominates Karen Witts as New Independent Board Member
January 21, 2022
·
6 min read
